Biovica’s DiviTum – Strong prognostic marker in operable breast cancer

Uppsala, Sweden, November 20, 2019. Biovica, active in cancer biomarkers, today announced clinical data that demonstrate DiviTum as a strong prognostic marker in operable breast cancer. The results will be presented at the San Antonio Breast Cancer Symposium, SABCS, December 10-14, 2019, the world´s largest scientific congress focusing on breast cancer.

2019-12-16T06:21:41+00:00 November 20th, 2019 08:20|News|

Biovicas DiviTum – Stark prognostisk markör vid operabel bröstcancer

Uppsala, Sverige, den 20 november 2019. Biovica, verksamt inom biomarkörer för cancer, meddelade idag kliniska data som visar att DiviTum är en stark prognostisk markör vid operabel bröstcancer. Resultaten kommer att presenteras på San Antonio Breast Cancer Symposium, SABCS, 10-14 december 2019, världens största vetenskapliga kongress med fokus på bröstcancer.

2019-12-16T06:21:39+00:00 November 20th, 2019 08:20|News|

Biovica’s DiviTum validated as a dynamic biomarker in metastatic breast cancer in collaboration with Institut Curie, Paris

Uppsala, Sweden, November 20, 2019. Biovica, active in cancer biomarkers, today announced that clinical data – demonstrating that DiviTum can be used as a dynamic, non-invasive biomarker for metastatic breast cancer patients treated with endocrine therapy and palbociclib – will be presented at the San Antonio Breast Cancer Symposium, December 10-14, 2019, the world´s largest scientific congress focusing on breast cancer.

2019-12-16T06:21:41+00:00 November 20th, 2019 08:00|News|

Biovicas DiviTum validerad som en dynamisk biomarkör för spridd bröstcancer i samarbete med Institut Curie, Paris

Uppsala, den 20:e november 2019. Biovica, verksamt inom biomarkörer för cancer, meddelade idag att kliniska data – som visar att DiviTum kan användas som en dynamisk, icke-invasiv biomarkör för patienter med spridd bröstcancer som behandlas med endokrin terapi och palbociclib – kommer att presenteras vid San Antonio Breast Cancer Symposium, 10-14 december 2019, världens största vetenskapliga kongress med fokus på bröstcancer.

2019-12-16T06:21:39+00:00 November 20th, 2019 08:00|News|

Biovica strengthens with new R&D Director

Uppsala, November 15, 2019. Biovica, active in cancer diagnostics, today announced that Otti Bengtsson Gref has been appointed new R&D Director and will be part of the management team. She most recently comes from the role as R&D Director at Cavidi.

2019-12-16T06:21:42+00:00 November 15th, 2019 08:00|Regulatory|